0 CIRM: Phase III clinical trial targeting Lou Gehrig’s disease gets US$15.9 million investment
The California Institute for Regenerative Medicine (CIRM) announces that it is investing $15.9 million in a therapy to tackle ALS.
Browsing: Movement disorders
0 NCTalks on neuromodulation in children: an interview with Jean-Pierre Lin, President of the British Paediatric Neurology Association
Dr Lin tells Lauren Pulling (Editor, NC) about his work as a pediatric neurologist, and recent advances in deep brain stimulation for infants.
0 #NCintroduces… Going through the motions: how modern techniques have changed the face of Parkinson’s research
Tom Naughton introduces the circuitry underlying Parkinson’s disease, and how our understanding and new techniques have advanced hand-in-hand to bring us to where we are now.
0 NCTalks with Jerrold Vitek: Parkinson’s, neuromodulation and collaboration
Dr Vitek discusses the Neuromodulation Research Center, progression in the field, and the biggest challenges associated with developing new neuromodulation therapies for conditions such as Parkinson’s disease.
0 Parkinson’s disease: asparagine endopeptidase as a potential drug target
The enzyme asparagine endopeptidase could be a key mediator in the cleavage and aggregation of alpha-synuclein in Parkinson’s disease.
0 EAN 2017: Guillain-Barré syndrome risk associated with month of birth
October babies are more likely to develop the syndrome, according to a study presented at the Congress of the European Academy of Neurology (Amsterdam, The Netherlands).
0 EAN 2017: Parkinson’s severity linked to hypertension
Researchers have provided evidence indicating that patients with hypertension suffer from more severe Parkinson’s disease than those with normal blood pressure.
0 iTBS brain stimulation reduces spasticity in spinal cord injury patients
A new study has demonstrated the potential of excitatory intermittent theta burst stimulation (iTBS) for reducing spasticity in patients with spinal cord injury.
1 Parkinson’s is partly an autoimmune disease, new study states
Researchers have found the first evidence that autoimmunity plays a role in Parkinson’s disease, showing that T cells recognize α-synuclein peptides.
0 Huntington’s pathology alleviated by CRISPR/Cas9 gene editing
An international research team have shown that gene editing reverses Huntington’s symptoms without off-target effects in a mouse model.